

Terumo Revises Interim Dividend Distribution and Year-End Dividends Forecast for Fiscal Year Ending March 31, 2023

TOKYO, JAPAN – November 10, 2022 – Terumo Corporation (TSE: 4543) decided at the Board of Directors meeting held on November 10, 2022 to distribute retained earnings as of September 30, 2022. Also, both the year-end dividends and the dividends forecast per share for fiscal year ending March 31, 2023 will be revised upwards as described below.

1. Details of Interim Dividends

	Decided Dividends	Previous Forecast	FY2021 Interim
		(As of May 12, 2022)	Dividends
Date of Record	September 30,	September 30,	September 30,
	2022	2022	2021
Dividends per Share	19.00 JPY	18.00 JPY	16.00 JPY
Total Amount of Dividends	14.3 billion JPY		12.1 billion JPY
Effective Payout Date	December 5, 2022		December 3, 2021
Source of Dividends	Retained earnings		Retained earnings

2. Details of the Revision

	Dividends per Share		
	End of Second Quarter	End of Fiscal Year	Annual
Previous Forecast	18.00 JPY	18.00 JPY	36.00 JPY
Revised Forecast		19.00 JPY	38.00 JPY
FY2022 Actual (Ending March 31, 2023)	19.00 JPY		
FY2021 Actual (Ended March 31, 2022)	16.00 JPY	18.00 JPY	34.00 JPY

(Reference) FY2022 Guidance: Profit attributable to owners of parent = 100 billion JPY

3. Reason of revision

As a measure to secure high profit margins and sustainable growth, Terumo is committed to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo will aim to steadily increase its dividend payouts to shareholders and has set a mid to long-term dividend payout ratio target of 30%.

Based on the above policy and recent financial results, the company decided to increase the interim dividend distribution to 19.00 JPY and year-end dividends to 19.00 JPY per share.

Disclaimer

Among the information that Terumo discloses, the forward-looking statements contain potential risks and uncertainty since these are made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results might differ from those statements due to various factors.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.